

The Radiosensitizing Agent 7-Hydroxystaurosporine (UCN-01) Inhibits the DNA Damage Checkpoint Kinase hChk1¹

Erica C. Busby, Dru F. Leistriz, Robert T. Abraham, Larry M. Karnitz, and Jann N. Sarkaria²

Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905 [E. C. B., D. F. L., L. M. K., J. N. S.], and Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710 [R. T. A.]

Abstract

The investigational anticancer agent 7-hydroxystaurosporine (UCN-01) abrogates the G₂ checkpoint in tumor cells and sensitizes them to the lethal effects of genotoxic anticancer agents. On the basis of the role of the Cdc25C phosphatase in maintenance of this damage-inducible checkpoint, we hypothesized that UCN-01 inhibits a component of the signal transduction pathway that modulates Cdc25C phosphorylation. Of the three kinases known to phosphorylate Cdc25C on Ser²¹⁶, both checkpoint kinase 1 (hChk1) and Cdc25C-associated protein kinase 1 (cTAK1) were potently inhibited by UCN-01 with IC₅₀s of 11 and 27 nM, respectively. Treatment of K562 erythroleukemia cells with similar drug concentrations resulted in decreased levels of Ser²¹⁶ phosphorylation of Cdc25C and complete disruption of the γ -radiation-induced G₂ checkpoint. In contrast to hChk1, the hChk2 kinase was 100-fold more resistant to inhibition by UCN-01 (IC₅₀, 1040 nM). These results suggest that disruption of the DNA damage-induced G₂ checkpoint by UCN-01 is mediated through the inhibition of the Cdc25C kinases, hChk1 and cTAK1, and that hChk2 activity is not sufficient to enforce the G₂ checkpoint in cells treated with a pharmacological inhibitor of hChk1.

Introduction

DNA damage-inducible cell cycle checkpoints are complex signal transduction networks that integrate the cellular responses to genotoxic insults by arresting cell cycle progression during the repair of DNA damage or the induction of apoptosis. The integrity of these checkpoint pathways is critical for maintenance of genomic stability and cellular recovery from genotoxic damage. In genetic models, loss of the G₂-M checkpoint leads to an increased sensitivity to DNA-damaging agents, suggesting that small molecule inhibitors of the G₂-M checkpoint response might be useful in cancer therapy as radio- and chemosensitizing agents (1). In fact, UCN-01³ is one of several compounds that abrogates the G₂-M checkpoint at concentrations associated with sensitization of cells to DNA-damaging agents (2, 3). Because UCN-01 inhibits multiple protein kinases (4), the identification of the molecular target(s) responsible for UCN-01-mediated checkpoint abrogation could facilitate the identification of more selective second-generation checkpoint inhibitors.

The induction of a G₂ arrest after DNA damage depends, in part, on inhibition of cyclin B1/Cdk1 activity through phosphorylation of the Cdk1 subunit at Thr¹⁴ and Tyr¹⁵ (5). The dynamic changes in the

phosphorylation of Cdk1 during both the normal cell cycle and in response to DNA damage are controlled by an interplay between the enzymatic activities of the Wee1-like kinases and the Cdc25C phosphatase. In recent years, the signaling pathways controlling Cdc25C activation and subcellular localization have been partially elucidated. Current models suggest that the serine-threonine kinases hChk1 and hChk2 are activated by DNA damage signaling pathway(s) dependent on the ATM family of protein kinases (6–8). Activated hChk1 and/or hChk2 then phosphorylate Cdc25C on Ser²¹⁶, which creates a consensus binding site for 14-3-3 proteins. In undamaged interphase cells, Ser²¹⁶ also is phosphorylated by a third, constitutively active kinase, the Cdc25C-associated protein kinase (cTAK1). Association with 14-3-3 proteins leads to sequestration of phosphorylated Cdc25C in the cytoplasm and prevents premature dephosphorylation of Cdk1 and activation of the cyclin B1/Cdk1 complex.

Staurosporine and UCN-01 are capable of inhibiting the phosphotransferase activities of several serine-threonine protein kinases (4). Because the kinase activity of Wee1 is resistant to UCN-01 (9), we hypothesized that the mechanism of UCN-01-mediated checkpoint abrogation might involve inhibition of one or more of the kinases that regulate Cdc25C. In this study, we show that UCN-01 inhibits hChk1 and cTAK1 at drug concentrations associated with abrogation of the G₂ checkpoint. In contrast, hChk2 was relatively resistant to checkpoint inhibitory concentrations of UCN-01. These data identify hChk1 as a relevant molecular target for UCN-01 and suggest that specific hChk1 inhibitors will efficiently disrupt the G₂ checkpoint.

Materials and Methods

Cell Culture, Antibodies, and Plasmid Constructs. The K562 erythroleukemia cell line was maintained in RPMI 1640 (Life Technologies, Inc.) containing 10% fetal bovine serum. UCN-01 (generously provided by Dr. Edward Sausville, National Cancer Institute) was dissolved in DMSO and stored at –20°C. The viral HA-specific mouse monoclonal antibody, HA.11, was purchased from Babco, and a Cdc25C-specific polyclonal rabbit antiserum (C-20) was purchased from Santa Cruz Biotechnology. hChk1 and hChk2 were amplified by PCR from a human testes cDNA library (Clontech), and the respective full-length cDNA was cloned into the pEF-BOS plasmid with COOH-terminal tandem HA epitope tags (HA₂). cTAK1 was PCR amplified from the same cDNA library and cloned into the pcDNA3.1+ plasmid with an NH₂-terminal tandem HA epitope tag. The coding sequence for cTAK1 differed from that published previously and contained a single amino acid substitution (G443S; Ref. 10). This difference was present in all five cDNA clones sequenced and in nine human sequences from the dbEST database (GenBank), which suggests that this variant represents a polymorphism of the cTAK1 sequence. The kinase dead point-mutants, Chk1 (D130A), Chk2 (D347A), and cTAK1 (D196N), were generated by site-directed mutagenesis using the GeneEditor kit from Promega Corp. The GST-Cdc25C^{200–256} fusion protein was generated as described previously (11).

Immune Complex Kinase Assays. The hChk1 and hChk2 kinase assays were performed as described previously for hChk1 (11). Kinase assays for cTAK were performed essentially as described for hChk1 except for minor changes in the immunoprecipitation conditions. K562 cells transiently expressing epitope-tagged cTAK1 were lysed in buffer (20 mM HEPES, 0.15 M NaCl,

Received 12/9/99; accepted 3/2/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by the Mayo Foundation, Mayo Cancer Center, and by grants from the Fraternal Order of Eagles and the NIH CA52995 (to R. T. A.), CA69709 (to J. N. S.), and CA80829 (to J. N. S.).

² To whom requests for reprints should be addressed, at Mayo Foundation, Guggenheim Building, Room 1301, 200 First Street S.W., Rochester, MN 55905. Phone: (507) 266-5232; Fax: (507) 284-3906; E-mail: sarkaria.jann@mayo.edu.

³ The abbreviations used are: UCN-01, 7-hydroxystaurosporine; Cdk, cyclin-dependent kinase; ATM, ataxia telangiectasia *mutated*; HA, hemagglutinin; PKC, protein kinase C; HU, hydroxyurea; hChk, checkpoint kinase; cTAK1, Cdc25C-associated protein kinase 1; ATR, AT and Rad3-related.

1.5 mM MgCl₂, and 1 mM EGTA, pH 7.4) containing 1 mM DTT, 10 μg/ml aprotinin, 5 μg/ml pepstatin, 5 μg/ml leupeptin, 20 nM microcystin, 10 mM β-glycerophosphate, and 0.5% Triton X-100. After immunoprecipitation with HA.11 and protein A-Sepharose beads, immunoprecipitates were washed twice in lysis buffer, twice in high-salt buffer [0.1 M Tris-HCl (pH 7.4), 0.6 M NaCl], and twice in kinase buffer [50 mM Tris (pH 7.4), 10 mM MgCl₂]. Kinase assays were then performed as outlined previously for hChk1 (11). All kinase reactions were performed under linear reaction conditions.

Flow Cytometry. Ethanol-fixed cells were stained with propidium iodide and analyzed by flow cytometry as described previously (12).

Cdc25C Mobility. K562 cells were treated with graded concentrations of UCN-01 and then lysed in TNE buffer [50 mM Tris (pH 8.0), 150 mM sodium chloride, 5 mM EDTA, 1% NP40, and 0.1% SDS] containing 0.1 mM sodium orthovanadate, 10 μg/ml aprotinin, 5 μg/ml pepstatin, 5 μg/ml leupeptin, 20 nM microcystin, 200 μM dephostatin, 10 μM cypermethrin, 200 μM okadaic acid, and 25 nM tautomycin. The detergent-soluble proteins were then processed for immunoblotting with Cdc25C-specific antisera.

hChk1/hChk2 Mobility Shift. K562 cells were lysed in TNE buffer containing 1 mM DTT, 10 μg/ml aprotinin, 5 μg/ml pepstatin, 5 μg/ml leupeptin, 20 nM microcystin, and 10 mM β-glycerophosphate. The detergent-soluble proteins were then processed for immunoblotting with the HA.11 monoclonal antibody.

Statistics. All statistical analyses were performed with the Sigma Plot 5.0 (SPSS) software package. The kinase inhibition data were fit with the Hill four-parameter model by the least-squares method. The concentrations of UCN-01 resulting in half-maximal inhibition (IC₅₀) for the respective kinases were calculated by solving the model for a relative activity of 0.5.

Results and Discussion

As a preliminary step toward identifying relevant molecular target(s) inhibited by UCN-01, we developed a UCN-01 concentration-inhibition relationship for disruption of the G₂ checkpoint in exponentially growing K562 erythroblastoid leukemia cells. K562 cells were treated with 8 Gy γ-radiation and graded concentrations of UCN-01. After 21 h, ~80% of cells were arrested in G₂ after irradiation alone, which is consistent with the lack of a DNA damage-inducible G₁ checkpoint in this p53-null cell line. In contrast, treatment of cells with 100 nM UCN-01 completely abrogated the radiation-induced G₂ arrest (Fig. 1). When parallel samples were treated with the microtubule inhibitor nocodazole, nearly all irradiated cells were arrested with a tetraploid DNA content with or without UCN-01 treatment (Fig. 1A and data not shown). These results demonstrate that the drug-treated cells traversed the G₂-M checkpoint and were not simply arrested in G₁. On the basis of these data, we predicted that one or more kinases in the G₂ checkpoint pathway would be inhibited by UCN-01 at concentrations of ≤100 nM.

The phosphorylation of Cdc25C on Ser²¹⁶ is an important upstream event during the induction of a G₂ arrest in cells exposed to DNA-damaging agents. Three protein kinases (hChk1, hChk2, and cTAK1) are thought to be capable of phosphorylating the Ser²¹⁶ site in mammalian cells. To determine which, if any, of these protein kinases might be relevant targets inhibited by UCN-01, we examined the sensitivity of these kinases to UCN-01 in immune-complex kinase assays. Epitope-tagged, wild-type, or kinase-dead (D130A) hChk1 was immunoprecipitated from transiently transfected K562 cells, and immune complex kinase assays were performed with a GST-Cdc25C fusion protein as a substrate. Wild-type hChk1 phosphorylated GST-Cdc25C^{200–256} to a significantly higher level than the background activity present in the kinase-dead control, and incubation with 300 nM UCN-01 reduced wild-type hChk1 kinase activity to background (Fig. 2A). When the concentration of UCN-01 was varied, an IC₅₀ of 11 nM was observed. In previous work evaluating the effects of UCN-01 on PKC, there was little difference in the concentrations of UCN-01 required to inhibit PKC kinase activity *in vitro* and a PKC-dependent signaling pathway in intact cells (13). This suggests




Fig. 1. Effects of UCN-01 on the G₂ checkpoint. A, K562 cells were treated with 0 or 8 Gy γ-radiation and graded concentrations of UCN-01. In the indicated samples, 0.3 μg/ml of the nocodazole (*noc*) was added at the time of irradiation. After 21 h, cells were fixed in 70% ethanol, and cell cycle distributions were determined by staining with propidium iodide and analysis with flow cytometry. Three independent trials were performed. Histograms of red fluorescence intensity (DNA content) from 20,000 ungated events are shown from a representative experiment. The percentage of cells arrested in G₂ are listed on each histogram. B, the results are summarized graphically for cells treated with 8 Gy and graded concentrations of UCN-01. The data are presented as the means from three independent trials; bars, SE.

that the intracellular concentration of UCN-01 approaches that present in the surrounding medium. Thus, the close correlation between the effects of UCN-01 on the integrity of the G₂ checkpoint in intact cells and on hChk1 kinase activity *in vitro* suggests that inhibition of hChk1 may contribute to UCN-01-mediated checkpoint disruption.

Recent studies in mammalian cells have demonstrated that γ-radiation-induced hChk2 activation requires ATM kinase activity and raise the possibility that hChk2 may be involved in regulation of the G₂ checkpoint (6, 14, 15). Because recombinant hChk2 can phosphorylate Cdc25C on Ser²¹⁶ *in vitro*, we predicted that inhibition of hChk2 by UCN-01 would be required for abrogation of the G₂ checkpoint. Contrary to this hypothesis, the kinase activity of hChk2 was 100-fold more resistant to the inhibitory effects of UCN-01 (Fig. 2B; IC₅₀, 1040 nM). On the basis of the sensitivity of the G₂ checkpoint to UCN-01 (Fig. 1B), our data suggest that concomitant inhibition of both hChk1 and hChk2 kinase activities is not required for G₂ checkpoint abrogation.

The phosphorylation of Cdc25C on Ser²¹⁶ and the exclusion of




Fig. 2. Inhibition of hChk1, hChk2, and cTAK1 activities by UCN-01. K562 erythroblastoid leukemia cells were transfected with the indicated constructs for hChk1 (A), hChk2 (B), and cTAK1 (C), and cells were lysed 18–20 h later. Epitope-tagged kinases were immunoprecipitated with an HA-specific monoclonal antibody, and the immunoprecipitates were preincubated on ice with buffer alone or $2\times$ final concentrations of UCN-01. Kinase reactions were initiated by addition of $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ and the GST-Cdc25C^{200–256} kinase substrate. The reaction products were resolved by SDS-PAGE, and the incorporation of $^{32}\text{P}_i$ into GST-Cdc25C^{200–256} was determined by phosphorimaging. Equal expression of epitope-tagged proteins was then confirmed by immunoblotting with an HA-specific antibody. The final concentration of UCN-01 used in the indicated samples was 300 nM. In experiments using graded concentrations of UCN-01, the kinase activity at a given drug concentration was normalized to that measured in the untreated control, and the results are summarized graphically. Data points represent the means from three independent experiments; bars, SE. The data were fit with a Hill four-parameter regression model, and IC_{50} s were calculated.

Cdc25C from the nucleus are maintained throughout interphase. In unstressed cells, this phosphorylation is presumably maintained by the cTAK1 kinase (10). We evaluated the sensitivity of cTAK1 to UCN-01 to complete our survey of known protein kinases that can phosphorylate Cdc25C on Ser²¹⁶. Interestingly, cTAK1 was nearly as sensitive as hChk1 to the inhibitory effects of UCN-01 in immunocomplex kinase assays with an IC_{50} of 27 nM (Fig. 2C). Although cTAK1 has no known function in the DNA damage checkpoint responses, we cannot exclude the possibility that inhibition of cTAK1 kinase activity by UCN-01 could contribute to the checkpoint inhibitory effects of this drug.

The results presented, to this point, support the hypothesis that the checkpoint inhibitory effects of UCN-01 are related to the inhibition of hChk1 but not hChk2 kinase activities. Both hChk1 and hChk2 are inducibly phosphorylated in response to genotoxic agents, and these modifications are presumed to be important in checkpoint activation (6, 16). Therefore, a UCN-01-induced block in an upstream event modulating hChk1 or hChk2 activation also might lead to abrogation of the G₂ checkpoint. To evaluate the effects of UCN-01 on the integrity of these upstream signaling pathways, we assessed whether UCN-01 affected the DNA damage-induced phosphorylation of transiently expressed hChk1 and hChk2 in K562 cells treated with 10 mM HU or 20 Gy γ -radiation. The mobility of hChk1 on SDS-PAGE was appreciably retarded 1 h after irradiation or continuous exposure to HU (data not shown), and pretreatment with 1 μM UCN-01 had no

effect on this hChk1 mobility shift (Fig. 3A). Likewise, the radiation-induced mobility shift of hChk2 also was unchanged by UCN-01 pretreatment (Fig. 3B). Consistent with this observation, we have shown previously that the ATM kinase, which functions directly upstream of hChk2, also is resistant to inhibition by UCN-01 (11). Thus, in contrast to the protein kinase activity of hChk1 itself, the pathways leading to hChk1 and hChk2 activation in damaged cells are not sensitive to UCN-01.

The maintenance of Cdc25C phosphorylation on Ser²¹⁶ after DNA damage is thought to prevent premature progression from G₂ into mitosis. Throughout interphase, the vast majority of Cdc25C is phosphorylated on Ser²¹⁶ (17). This modification can be detected by the reduced mobility of Cdc25C on SDS-PAGE (18). Because UCN-01 inhibits two protein kinases that modify the regulatory Ser²¹⁶ site, we hypothesized that UCN-01 might affect the phosphorylation status of Cdc25C in irradiated cells. To test this, K562 cells were exposed to 12 Gy γ -radiation. After 16 h, 95% of cells were arrested in G₂. Treatment of this G₂-arrested cell population with 100 nM UCN-01 resulted in a significant increase in the nonphosphorylated, relative to the phosphorylated, form of Cdc25C within 15 min of drug addition.⁴ Moreover, graded concentrations of UCN-01 resulted in considerable accumulation of the nonphosphorylated Cdc25C species (Fig. 3C) at

⁴ J. N. Sarkaria and D. F. Leistriz, unpublished data.

concentrations associated with significant inhibition of hChk1 and cTAK1 kinase activities (Fig. 2, A and C). In combination with our cell cycle data (Fig. 1B), these results are consistent with loss of G₂ checkpoint integrity at UCN-01 concentrations associated with marked inhibition of intracellular hChk1 and cTAK1 kinase activities.

The ATM and ATR proteins appear to control downstream signaling events in the G₂ checkpoint pathway (19–21). We have shown previously that the checkpoint inhibitory effects of the radiosensitizing agent caffeine were related to the inhibition of ATM and ATR kinase activities (11). Both epistasis experiments in yeast and genetic studies in mammalian cells suggest that these protein kinases participate in the activation of hChk1 and hChk2, which can then phosphorylate downstream targets such as Cdc25C. The present findings suggest that inhibition of hChk1 and cTAK1 kinase activities is sufficient to abrogate the G₂ checkpoint. Strikingly, the relative resistance of the hChk2 kinase to inhibition by UCN-01 suggests that activation of the hChk2 kinase, in the absence of hChk1 and cTAK1 kinase activities, is insufficient to maintain the γ -radiation-induced G₂ arrest. This implies either that phosphorylation of Cdc25C by hChk2 alone is insufficient to arrest cell cycle progression or that hChk2 is not a physiologically relevant protein kinase for Cdc25C in DNA-damaged cells. Although we cannot exclude the potential role for cTAK1 in the induction and/or maintenance of the checkpoint, our results reinforce the notion that a specific inhibitor of hChk1 would be an effective inhibitor of the G₂ checkpoint.

Recent evidence suggests that the therapeutic efficacies of certain DNA-damaging anticancer drugs are causally related to the loss of normal DNA damage checkpoint controls during the process of carcinogenesis (22, 23). These studies suggest that agents that interfere with checkpoint-related proteins may show selectivity for tumor cells bearing intrinsic defects in specific checkpoint pathways. One of the




Fig. 3. Effects of UCN-01 on hChk1, hChk2, and Cdc25C phosphorylation. K562 cells were transiently transfected with constructs for hChk1 (A) and hChk2 (B). After 18 h, cells were incubated with 1 μ M UCN-01 for 15 min before exposure to 10 mM HU, 20 Gy γ -radiation (γ) or control treatment (C). Cells were lysed after 60 min, and soluble proteins were resolved by SDS-PAGE. Proteins were transferred onto polyvinylidene difluoride membranes and then immunoblotted with an HA-specific monoclonal antibody. The results shown are representative of those obtained in three independent trials. C, Cdc25C mobility shift. K562 cells were exposed to 12 Gy γ -radiation. After 16 h, cells were treated with graded concentrations of UCN-01. At this time, 95% of cells were arrested in G₂-M, as determined by flow cytometry (data not shown). Cells were lysed 60 min after drug treatment, and soluble proteins were resolved by SDS-PAGE. Proteins were transferred onto a polyvinylidene difluoride membrane and then immunoblotted with Cdc25C antiserum. The results shown are representative of those obtained in three independent trials.




Fig. 4. Model for pharmacological G₂ checkpoint abrogation. Two parallel signal transduction pathways prevent premature progression from G₂ into mitosis in the face of damaged DNA. DNA damage induces the accumulation of 14-3-3 σ in a p53-dependent manner and leads to exclusion of cyclin B1/Cdk1 complexes from the nucleus. Unrepaired DNA damage also leads to activation of hChk1, which then phosphorylates Cdc25C on Ser²¹⁶. Phosphorylated Cdc25C is then sequestered in the cytoplasm after association with 14-3-3 ϵ . Pharmacological inhibition of the hChk1-dependent checkpoint pathway will lead to loss of checkpoint integrity only if the p53-dependent signaling pathway has been compromised previously during the process of oncogenesis.

most common mutations that affects checkpoint integrity is inactivation of the p53 tumor suppressor protein. Because p53 functions in several checkpoint pathways (19), the loss of p53 might leave tumor cells more vulnerable to pharmacological inhibition of components of the remaining checkpoints in these cells. The expected outcome of checkpoint inhibitor treatment in this setting would be a selective increase in the sensitivities of cancer cells to conventional genotoxic cancer therapies. In fact, both caffeine and UCN-01 selectively abrogate the G₂ checkpoint in tumor cells that have lost p53-dependent checkpoint controls (2, 24–26). The recent demonstration that homozygous deletion of 14-3-3 σ in HCT116 colon cancer cells compromises the G₂ checkpoint provides novel insight into a potential mechanism for the selective pharmacological inhibition of the G₂ checkpoint (Fig. 4). In normal cells, DNA damage leads to a p53-dependent accumulation of 14-3-3 σ , which binds to and sequesters cyclin B1/Cdk1 complexes in the cytoplasm (27). With cyclin B1/Cdk1 excluded from the nucleus, pharmacological disruption of the hChk1-dependent checkpoint pathway controlling Cdc25C localization will not lead to premature entry into mitosis. However, in tumor cells deficient in p53 function, the integrity of the G₂ arrest is solely dependent on the hChk1-dependent pathway, and disruption of this pathway could then lead to checkpoint abrogation.

Acknowledgments

We thank Drs. Scott Kaufmann and Junjie Chen for helpful advice and discussions and James Tarara and the other members of the Mayo Cancer Center Flow Cytometry Laboratory for expert technical assistance.

Note Added in Proof

After the resubmission of our revised manuscript, Graves *et al.* (P. R. Graves, *J. Biol. Chem.*, 275: 5600–5605, 2000) reported that UCN-01 potentially inhibits the kinase activity of hChk1 (IC₅₀, 25 nM) but not hChk2.

References

- Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. *Science* (Washington DC), 266: 1821–1828, 1994.

2. Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., and O'Connor, P. M. UCN-01: a potent abrogator of G₂ checkpoint function in cancer cells with disrupted p53. *J. Natl. Cancer Inst.*, **88**: 956–965, 1996.
3. O'Connor, P. M., and Fan, S. DNA damage checkpoints: implications for cancer therapy. *Prog. Cell Cycle Res.*, **2**: 165–173, 1996.
4. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxystaurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. *Biochem. Biophys. Res. Commun.*, **219**: 778–783, 1996.
5. Ohi, R., and Gould, K. L. Regulating the onset of mitosis. *Curr. Opin. Cell Biol.*, **11**: 267–273, 1999.
6. Matsuoka, S., Huang, M., and Elledge, S. J. Linkage of ATM to the cell cycle regulation by the Chk2 protein kinase. *Science (Washington DC)*, **282**: 1893–1897, 1998.
7. Nurse, P. Checkpoint pathways come of age. *Cell*, **91**: 865–867, 1997.
8. Weinert, T. A DNA damage checkpoint meets the cell cycle engine. *Science (Washington DC)*, **277**: 1450–1451, 1997.
9. Yu, L., Orlandi, L., Wang, P., Orr, M. S., Sederowicz, A. M., Sausville, E. A., Silvestrini, R., Watanabe, N., Piwnica-Worms, H., and O'Connor, P. M. UCN-01 abrogates G₂ arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. *J. Biol. Chem.*, **273**: 33455–33464, 1998.
10. Peng, C-Y., Graves, P. R., Ogg, S., Thoma, R. S., Byrnes, M. J., III, Wu, Z., Stephenson, M. T., and Piwnica-Worms, H. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14–3-3 protein binding. *Cell Growth Differ.*, **9**: 197–208, 1998.
11. Sarkaria, J. N., Busby, E. C., Tibbetts, R. S., Roos, P., Taya, Y., Karnitz, L. M., and Abraham, R. T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. *Cancer Res.*, **59**: 4375–4382, 1999.
12. Sarkaria, J. N., Tibbetts, R. S., Busby, E. C., Kennedy, A. P., Hill, D. E., and Abraham, R. T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. *Cancer Res.*, **58**: 4375–4382, 1998.
13. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. *Cell Growth Differ.*, **6**: 927–936, 1995.
14. Brown, A. L., Lee, C-H., Schwartz, J. K., Mitiku, N., Piwnica-Worms, H., and Chung, J. H. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. *Proc. Natl. Acad. Sci. USA*, **96**: 3745–3750, 1999.
15. Blasina, A., Weyer, I. V. d., Laus, M. C., Luyten, W. H., Parker, A. E., and McGowan, C. H. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. *Curr. Biol.*, **9**: 1–10, 1999.
16. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. Conservation of the chk1 checkpoint pathway in mammals: linkage of DNA damage to cdk regulation through Cdc25. *Science (Washington DC)*, **277**: 1497–1501, 1997.
17. Dalal, S. N., Schweitzer, C. M., Gan, J., and DeCaprio, J. A. Cytoplasmic localization of human Cdc25C during interphase requires an intact 14-3-3 binding site. *Mol. Cell. Biol.*, **19**: 4465–4479, 1999.
18. Peng, C-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H. Mitotic and G₂ checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. *Science (Washington DC)*, **277**: 1501–1505, 1997.
19. Morgan, S. E., and Kastan, M. B. p53 and ATM: cell cycle, cell death and cancer. *Found. Cancer Res.*, **71**: 1–25, 1997.
20. Cliby, W. A., Roberts, C. J., Cimprich, K. A., Stringer, C. M., Lamb, J. R., Schreiber, S. L., and Friend, S. H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. *EMBO J.*, **17**: 159–169, 1998.
21. Keith, C. T., and Schreiber, S. L. PIK-related kinases: DNA repair, recombination and cell cycle checkpoints. *Science (Washington DC)*, **270**: 50–51, 1995.
22. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. *Nature (Lond.)*, **381**: 713–716, 1996.
23. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest *versus* cell death in cancer therapy. *Nat. Med.*, **3**: 1034–1036, 1997.
24. Yao, S-L., Akhtar, A. J., McKenna, K. A., Bedi, G. C., Sidransky, D., Mabry, M., Ravi, R., Collector, M. I., Jones, R. J., Sharkis, S. J., Fuchs, E. J., and Bedi, A. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34^{cdc2} kinase. *Nat. Med.*, **2**: 1140–1143, 1996.
25. Russell, K. J., Wiens, L. W., Demers, G. W., Galloway, D. A., Plon, S. E., and Groudine, M. Abrogation of the G₂ checkpoint results in differential radiosensitization of G₁ checkpoint-deficient and G₁ checkpoint-competent cells. *Cancer Res.*, **55**: 1639–1642, 1995.
26. Powell, S. N., DeFrank, J. S., Connell, P., Eogan, M., Preffer, F., Dombkowski, D., Tang, W., and Friend, S. Differential sensitivity of p53^(-/-) and p53^(+/+) cells to caffeine-induced radiosensitization and override of G₂ delay. *Cancer Res.*, **55**: 1643–1648, 1995.
27. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W., and Vogelstein, B. 14-3-3 σ is required to prevent mitotic catastrophe after DNA damage. *Nature (Lond.)*, **401**: 616–620, 1999.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

The Radiosensitizing Agent 7-Hydroxystaurosporine (UCN-01) Inhibits the DNA Damage Checkpoint Kinase hChk1

Erica C. Busby, Dru F. Leistriz, Robert T. Abraham, et al.

Cancer Res 2000;60:2108-2112.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/60/8/2108>

Cited articles This article cites 25 articles, 15 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/60/8/2108.full#ref-list-1>

Citing articles This article has been cited by 100 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/60/8/2108.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/60/8/2108>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.